When was Pantec Biosolutions founded?

Pantec Biosolutions was founded in 2006 and raised its 1st funding round 1 year after it was founded.

Where is Pantec Biosolutions located?

Pantec Biosolutions is headquartered in Ruggell, Liechtenstein.

How many employees does Pantec Biosolutions have?

As of Aug 31, 2026, the latest employee count at Pantec Biosolutions is 13.

Is Pantec Biosolutions a funded company?

Pantec Biosolutions is a funded company, having raised a total of $24.7M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Dec 07, 2007.

When was the latest funding round of Pantec Biosolutions?

Pantec Biosolutions' latest funding was a $***** Series B round on Jul 20, 2010, with participation from 0 investor.

Where does Pantec Biosolutions rank among its competitors?

Pantec Biosolutions ranks 850th amongst 1953 active competitors, of which 450 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was LifeMine Therapeutics, which secured $75M in Aug, 2026.

Who are the top competitors of Pantec Biosolutions?

Pantec Biosolutions' top competitors include Antheia, Transcenta and Akeso. Among them, LifeMine Therapeutics secured the most recent funding round in August, 2026.

Pantec Biosolutions - 2026 Company Profile, Team, Funding & Competitors

Company Details

Pantec Biosolutions is a drug delivery development company working on laser-assisted micro-poration for transdermal drug delivery. Their proprietary system, Precise Laser EpidermAl SystEm, (PLEASE) is available commercially in Europe for patch-mediated transdermal delivery of large molecule proteins, intradermal and epidermal clinical interventions. The specialty of the company is its focus on the transdermal delivery of large biological molecules. The intradermal delivery can be used for precise and stable delivery of siRNA and other biological compounds.The epidermal delivery can be used for the delivery of vaccines and immunological compounds.

Website: pantec-biosolutions.com/en
Social
Email ID: *****@pantec-biosolutions.com
Phone Number: +423 **********

Key Metrics

Founded Year

2006

Location

Ruggell, Liechtenstein

Stage

Series B

Total Funding

$24.7M in 2 rounds

Latest Funding Round

Series B, Jul 20, 2010, $*****

Investors

Gamma Capital Partners

Ranked

850^th among 1953 active competitors

Employee Count

13 as on Aug 31, 2026

Similar Companies

Antheia & 2659 more

View Pantec Biosolutions' full profile

Pantec Biosolutions has raised a total funding of $24.7M over 2 rounds. Its first funding round was on Dec 07, 2007. Pantec Biosolutions has 1 institutional investor.

Here is the list of recent funding rounds of Pantec Biosolutions:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 20, 2010	8866929	Series B	5719007	3983576	8647385	6695100
Dec 07, 2007	9997439	Series A	4962140	5550372	7933497	Gamma Capital Partners

Access funding benchmarks and valuations. Sign up today!

View details of Pantec Biosolutions's funding rounds and investors

The founders of Pantec Biosolutions are Werner Braun and Christof Bohler.

Here are the details of Pantec Biosolutions' key team members:

Werner Braun: Co-Founder of Pantec Biosolutions.
Christof Bohler: Co-Founder of Pantec Biosolutions.

View details of Pantec Biosolutions's Founder profiles and Board Members

Pantec Biosolutions' employee count trend

Pantec Biosolutions has 13 employees as of Aug 26. Here is Pantec Biosolutions's employee count trend over the years:

Employee count trend for Pantec Biosolutions

Uncover Pantec Biosolutions' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Pantec Biosolutions include Antheia, Transcenta and Akeso. Here is the list of Top 10 competitors of Pantec Biosolutions, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
2nd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
3rd	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Loayal Valley Capital, Sino Biopharmaceutical ... & 18 others	65/100
4th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, Atlas Venture ... & 14 others	64/100
5th	Fermentalg 2005, Libourne (France), Public	Innovating with algae for sustainable solutions in nutrition and environmental impact	$30.3M	Demeter, Smalt Capital & 14 others	63/100
6th	Microban 1994, Huntersville (United States), Acquired	Antimicrobial and odor control technologies for durable product protection and freshness	$64.6M	TA Associates, UBS & 1 others	63/100
7th	LifeMine Therapeutics 2016, Watertown (United States), Series E	Developer of novel drugs from fungi via genome mining and recombinant overexpression	$563M	Fidelity Investments, 6 Dimensions Capital ... & 17 others	63/100
8th	Dewpoint Therapeutics 2018, Boston (United States), Series D	Developer of small molecule based therapeutics	$364M	Maverick Ventures, SoftBank Vision Fund & 16 others	62/100
9th	One Biosciences 2020, Paris (France), Series A	Developer of single-cell therapeutics solutions to treat multiple health disorders	$22.4M	BLAST Premier, Redmile Group & 6 others	62/100
10th	Avalyn Pharma 2011, Seattle (United States), Public	Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis	$389M	Perceptive Advisors, Norwest & 22 others	61/100
850th	Pantec Biosolutions 2006, Ruggell (Liechtenstein), Series B	Drug delivery development company working on laser-assisted micro-poration for transdermal drug delivery	$24.7M	Gamma Capital Partners	28/100